Literature DB >> 10383365

HFE genotype in patients with hemochromatosis and other liver diseases.

B R Bacon1, J K Olynyk, E M Brunt, R S Britton, R K Wolff.   

Abstract

BACKGROUND: Hereditary hemochromatosis is a common inherited disorder of iron metabolism. The gene HFE, which contains two missense mutations (C282Y and H63D), was recently identified.
OBJECTIVE: To determine how HFE genotyping for the C282Y and H63D mutations contributes to the diagnosis of hemochromatosis and to determine the prevalence of HFE mutations in a group of patients with liver disease.
DESIGN: Cross-sectional study.
SETTING: Academic medical center. PATIENTS: 66 patients with hereditary hemochromatosis and 132 referred patients with other liver diseases. MEASUREMENTS: At initial diagnosis, fasting transferrin saturation, ferritin level, routine chemistry panel, and complete blood count were determined. Percutaneous liver biopsy was done on all patients for histologic analysis and measurement of hepatic iron concentration and hepatic iron index. HFE genotyping for the C282Y and H63D mutations was done on all patients by using genomic DNA samples.
RESULTS: Of the 66 patients with hemochromatosis diagnosed on the basis of serum iron studies and liver biopsy findings, 60 (91%) were C282Y homozygotes, 2 (3%) were compound heterozygotes, 1 (1.5%) was a C282Y heterozygote, 2 (3%) were H63D heterozygotes, and 1 (1.5%) was negative for both mutations. Of the 132 patients with liver disease, 6 (5%) were C282Y homozygotes, 8 (6%) were compound heterozygotes, 6 (5%) were C282Y heterozygotes, 5 (4%) were H63D homozygotes, 20 (15%) were H63D heterozygotes, and 87 (66%) were negative for both mutations. All 66 C282Y homozygotes had an elevated hepatic iron concentration, and 65 of the 66 patients (98%) had a transferrin saturation of at least 45%. Ten of the 66 patients (15% [95% CI, 7.5% to 26%]) had a hepatic iron index less than 1.9 mmol/kg per year; hemochromatosis was not suspected in 6 of the 10 patients before genotyping. Cirrhosis or substantial hepatic fibrosis was not seen in any (0% [CI, 0% to 18%]) of the 19 patients younger than 40 years of age who were homozygous for the C282Y mutation.
CONCLUSIONS: All 66 patients homozygous for the C282Y mutation of HFE had an elevated hepatic iron concentration, but approximately 15% of these patients did not meet a previous diagnostic criterion for hemochromatosis (hepatic iron index > 1.9 mmol/kg per year). Determination of HFE genotype is clinically useful in patients with liver disease and suspected iron overload and may lead to identification of otherwise unsuspected C282Y homozygotes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383365     DOI: 10.7326/0003-4819-130-12-199906150-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  41 in total

Review 1.  Molecular pathogenesis of iron overload.

Authors:  D Trinder; C Fox; G Vautier; J K Olynyk
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 2.  Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies?

Authors:  Eng K Gan; Oyekoya T Ayonrinde; Debbie Trinder; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2010-02

3.  Hepatobiliary quiz-3 (2012).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-09

4.  The diagnosis and management of hereditary haemochromatosis.

Authors:  Paul Clark; Laurence J Britton; Lawrie W Powell
Journal:  Clin Biochem Rev       Date:  2010-02

Review 5.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

6.  An unusual case of hemochromatosis in an African-American man: case report and review of the literature.

Authors:  David A Labowitz; Jennifer Bontreger; Albert D Min
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

7.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

8.  A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver.

Authors:  David P Cormode; Gitte O Skajaa; Amanda Delshad; Nicole Parker; Peter A Jarzyna; Claudia Calcagno; Merav W Galper; Torjus Skajaa; Karen C Briley-Saebo; Heather M Bell; Ronald E Gordon; Zahi A Fayad; Savio L C Woo; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2011-03-01       Impact factor: 4.774

Review 9.  Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature.

Authors:  Nicholas G Angelopoulos; Anastasia K Goula; George Papanikolaou; George Tolis
Journal:  Osteoporos Int       Date:  2005-07-05       Impact factor: 4.507

10.  Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes.

Authors:  Raymond Cheng; James C Barton; Elizabeth D Morrison; Pradyumna D Phatak; Edward L Krawitt; Stuart C Gordon; Kris V Kowdley
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.